Amneal Pharmaceuticals, Inc. or Perrigo Company plc: Who Invests More in Innovation?

Amneal vs. Perrigo: A Decade of R&D Investment

__timestampAmneal Pharmaceuticals, Inc.Perrigo Company plc
Wednesday, January 1, 2014106735000152500000
Thursday, January 1, 2015136870000187800000
Friday, January 1, 2016204747000184000000
Sunday, January 1, 2017191938000167700000
Monday, January 1, 2018210451000218600000
Tuesday, January 1, 2019202287000187400000
Wednesday, January 1, 2020190585000177700000
Friday, January 1, 2021209563000122000000
Saturday, January 1, 2022200046000123100000
Sunday, January 1, 2023167778000122500000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Companies

In the competitive pharmaceutical industry, innovation is key to staying ahead. Amneal Pharmaceuticals, Inc. and Perrigo Company plc have been investing in research and development (R&D) to drive innovation. From 2014 to 2023, Amneal's R&D expenses grew by approximately 57%, peaking in 2018 with a 97% increase from 2014. Perrigo, on the other hand, saw a 20% increase in R&D spending over the same period, with a notable peak in 2018. Despite fluctuations, both companies have shown a commitment to innovation, with Amneal consistently outspending Perrigo in recent years. This trend highlights Amneal's aggressive strategy to lead in pharmaceutical advancements. As the industry evolves, these investments could be pivotal in determining market leadership and future breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025